iCo-007, iCo’s lead Diabetes Macular Edema candidate, has been featured in an article in the Journal of Diabetes Science and Technology, a peer-reviewed scientific e-journal.
iCo-007 is a second-generation antisense drug discovered by Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and licensed to iCo. Potential benefits of second-generation antisense drugs, like iCo-007, are expected to include an extended half-life, resulting in less frequent intravitreal drug administration, and a good safety profile. iCo-007 targets multiple growth factors in addition to VEGF. Multiple growth factors seem to play a critical role in the process of ocular angiogenesis and leakage.

Link:http://www.icotherapeutics.com/site/investor-relations/ico_therapeutics_publishes_review_of_diabetic_retinopathy_treatment/
Source:iCo